Sanofi Pasteur inks antibody discovery accord for influenza vaccine research

Sanofi Pasteur, the vaccines business of French pharma major Sanofi (Euronext: SAN), has entered into a collaborative research effort with privately-held Canadian biotech firm AbCellera Biologicals.

The project will use AbCellera’s single-cell screening platform to profile vaccine-specific human antibodies elicited by seasonal influenza vaccination and to generate large panels of human monoclonal antibodies with desired binding profiles to various influenza strains. Financial terms of the accord were not disclosed.

Carl Hansen, chief executive of AbCellera, commented: “AbCellera’s platform is a powerful approach for human immune profiling and antibody discovery. We are excited to be working with the Sanofi Pasteur team to help advance vaccine research.”